nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial

INTRODUCTION: The phase III MPACT trial in patients with metastatic pancreatic cancer (MPC) demonstrated superior efficacy of nab-paclitaxel (nab-P) plus gemcitabine (Gem) compared with Gem monotherapy, including the primary endpoint of overall survival (OS; median 8.7 vs. 6.6 months; hazard ratio [...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther
Main Authors: Tehfe, Mustapha, Dowden, Scot, Kennecke, Hagen, El-Maraghi, Robert, Lesperance, Bernard, Couture, Felix, Letourneau, Richard, Liu, Helen, Romano, Alfredo
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2016
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882352/
https://ncbi.nlm.nih.gov/pubmed/27085323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0327-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados